Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases.
Jachiet V, Ricard L, Hirsch P, Malard F, Pascal L, Beyne-Rauzy O, Peterlin P, Maria ATJ, Vey N, D'Aveni M, Gourin MP, Dimicoli-Salazar S, Banos A, Wickenhauser S, Terriou L, De Renzis B, Durot E, Natarajan-Ame S, Vekhoff A, Voillat L, Park S, Vinit J, Dieval C, Dellal A, Grobost V, Willems L, Rossignol J, Solary E, Kosmider O, Dulphy N, Zhao LP, Adès L, Fenaux P, Fain O, Mohty M, Gaugler B, Mekinian A; MINHEMON: French Network of dysimmune disorders associated with hemopathies. Jachiet V, et al. Among authors: natarajan ame s. Clin Exp Med. 2023 Jul;23(3):803-813. doi: 10.1007/s10238-022-00866-5. Epub 2022 Aug 11. Clin Exp Med. 2023. PMID: 35953763
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
Mekinian A, Zhao LP, Chevret S, Desseaux K, Pascal L, Comont T, Maria A, Peterlin P, Terriou L, D'Aveni Piney M, Gourin MP, Vey N, Rauzy OB, Grobost V, Bezanahary H, Dimicoli-Salazar S, Banos A, Wickenhauser S, De Renzis B, Durot E, Natarajan-Amé S, Voillat L, Chermat F, Lemaire K, Jachiet V, Himberlin C, Thépot S, Diaz JMT, Frenzel L, Gyan E, Denis G, Hirsch P, Kosmider O, Ades L, Fain O, Fenaux P. Mekinian A, et al. Among authors: natarajan ame s. Leukemia. 2022 Nov;36(11):2739-2742. doi: 10.1038/s41375-022-01698-8. Epub 2022 Sep 14. Leukemia. 2022. PMID: 36104395 Clinical Trial. No abstract available.
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Natarajan-Amé S, Park S, Ades L, Vey N, Guerci-Bresler A, Cahn JY, Etienne G, Bordessoule D, Ravoet C, Legros L, Cheze S, Stamatoullas A, Berger E, Schmidt A, Charbonnier A, Chaury MP, Braun T, Fenaux P, Dreyfus F; Groupe Francophone des Myélodysplasies (GFM). Natarajan-Amé S, et al. Br J Haematol. 2012 Jul;158(2):232-237. doi: 10.1111/j.1365-2141.2012.09153.x. Epub 2012 May 10. Br J Haematol. 2012. PMID: 22571447 Free article. Clinical Trial.
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C, Della Valle V, Couronné L, Scourzic L, Chesnais V, Guerci-Bresler A, Slama B, Beyne-Rauzy O, Schmidt-Tanguy A, Stamatoullas-Bastard A, Dreyfus F, Prébet T, de Botton S, Vey N, Morgan MA, Cross NC, Preudhomme C, Birnbaum D, Bernard OA, Fontenay M; Groupe Francophone des Myélodysplasies. Damm F, et al. Blood. 2012 Apr 5;119(14):3211-8. doi: 10.1182/blood-2011-12-400994. Epub 2012 Feb 17. Blood. 2012. PMID: 22343920 Free article.
Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level.
Legros L, Slama B, Karsenti JM, Vey N, Natarajan-Amé S, Watel E, Richard B, Bouabdallah K, Mannone L, Benchetrit M, Touitou I, Huault S, Durivault J, Ambroseti D, Hueber AO, Fenaux P, Dreyfus F; Groupe Francophone des Myélodysplasies. Legros L, et al. Ann Hematol. 2012 Jan;91(1):39-46. doi: 10.1007/s00277-011-1242-z. Epub 2011 May 7. Ann Hematol. 2012. PMID: 21553011 Clinical Trial.
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Adès L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Amé S, Fenaux P, Germing U, Dreyfus F, Park S. Santini V, et al. Among authors: natarajan ame s. Blood. 2013 Sep 26;122(13):2286-8. doi: 10.1182/blood-2013-07-512442. Blood. 2013. PMID: 24072851 Free article. No abstract available.
Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.
Fohrer C, Caillard S, Koumarianou A, Ellero B, Woehl-Jaeglé ML, Meyer C, Epailly E, Chenard MP, Lioure B, Natarajan-Ame S, Maloisel F, Lutun P, Kessler R, Moulin B, Bergerat JP, Wolf P, Herbrecht R. Fohrer C, et al. Br J Haematol. 2006 Sep;134(6):602-12. doi: 10.1111/j.1365-2141.2006.06228.x. Epub 2006 Aug 2. Br J Haematol. 2006. PMID: 16889621 Free article.
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.
Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, Tenedini E, Pieri L, Paoli C, Mannarelli C, Fjerza R, Rumi E, Stalbovskaya V, Squires M, Cazzola M, Manfredini R, Harrison C, Tagliafico E, Vannucchi AM; COMFORT-II Investigators; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators. Guglielmelli P, et al. Blood. 2014 Apr 3;123(14):2157-60. doi: 10.1182/blood-2013-11-536557. Epub 2014 Jan 23. Blood. 2014. PMID: 24458439 Free article. Clinical Trial.
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators. Vannucchi AM, et al. Haematologica. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11. Haematologica. 2015. PMID: 26069290 Free PMC article. Clinical Trial.
31 results